Literature DB >> 19681758

Skeletal muscle dysfunction in COPD: clinical and laboratory observations.

William D-C Man1, Paul Kemp, John Moxham, Michael I Polkey.   

Abstract

COPD (chronic obstructive pulmonary disease), although primarily a disease of the lungs, exhibits secondary systemic manifestations. The skeletal muscles are of particular interest because their function (or dysfunction) not only influences the symptoms that limit exercise, but may contribute directly to poor exercise performance. Furthermore, skeletal muscle weakness is of great clinical importance in COPD as it is recognized to contribute independently to poor health status, increased healthcare utilization and even mortality. The present review describes the current knowledge of the structural and functional abnormalities of skeletal muscles in COPD and the possible aetiological factors. Increasing knowledge of the molecular pathways of muscle wasting will lead to the development of new therapeutic agents and strategies to combat COPD muscle dysfunction.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19681758     DOI: 10.1042/CS20080659

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  21 in total

1.  The relationship between pulmonary emphysema and kidney function in smokers.

Authors:  Divay Chandra; Jason A Stamm; Paul M Palevsky; Joseph K Leader; Carl R Fuhrman; Yingze Zhang; Jessica Bon; Steven R Duncan; Robert A Branch; Joel Weissfeld; David Gur; Mark T Gladwin; Frank C Sciurba
Journal:  Chest       Date:  2012-09       Impact factor: 9.410

2.  Altered skeletal muscle mitochondrial phenotype in COPD: disease vs. disuse.

Authors:  Jayson R Gifford; Joel D Trinity; Oh-Sung Kwon; Gwenael Layec; Ryan S Garten; Song-Young Park; Ashley D Nelson; Russell S Richardson
Journal:  J Appl Physiol (1985)       Date:  2017-12-28

3.  Blood flow-restricted strength training displays high functional and biological efficacy in women: a within-subject comparison with high-load strength training.

Authors:  Stian Ellefsen; Daniel Hammarström; Tor A Strand; Erika Zacharoff; Jon E Whist; Irene Rauk; Håvard Nygaard; Geir Vegge; Marita Hanestadhaugen; Mathias Wernbom; Kristoffer T Cumming; Roar Rønning; Truls Raastad; Bent R Rønnestad
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-07-22       Impact factor: 3.619

Review 4.  Muscle wasting in animal models of severe illness.

Authors:  Milan Holecek
Journal:  Int J Exp Pathol       Date:  2012-05-08       Impact factor: 1.925

5.  MicroRNA-542 Promotes Mitochondrial Dysfunction and SMAD Activity and Is Elevated in Intensive Care Unit-acquired Weakness.

Authors:  Roser Farre Garros; Richard Paul; Martin Connolly; Amy Lewis; Benjamin E Garfield; S Amanda Natanek; Susannah Bloch; Vincent Mouly; Mark J Griffiths; Michael I Polkey; Paul R Kemp
Journal:  Am J Respir Crit Care Med       Date:  2017-12-01       Impact factor: 21.405

Review 6.  Muscle function in COPD: a complex interplay.

Authors:  Anna V Donaldson; Matthew Maddocks; Dario Martolini; Michael I Polkey; William D-C Man
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2012-08-17

7.  Ventilatory chemosensory drive is blunted in the mdx mouse model of Duchenne Muscular Dystrophy (DMD).

Authors:  Matias Mosqueira; Santhosh M Baby; Sukhamay Lahiri; Tejvir S Khurana
Journal:  PLoS One       Date:  2013-07-29       Impact factor: 3.240

8.  Pharmacological inhibition of GSK-3 in a guinea pig model of LPS-induced pulmonary inflammation: II. Effects on skeletal muscle atrophy.

Authors:  Koen J P Verhees; Nicholas A M Pansters; Hoeke A Baarsma; Alexander H V Remels; Astrid Haegens; Chiel C de Theije; Annemie M W J Schols; Reinoud Gosens; Ramon C J Langen
Journal:  Respir Res       Date:  2013-11-01

9.  Growth differentiation factor-15 is associated with muscle mass in chronic obstructive pulmonary disease and promotes muscle wasting in vivo.

Authors:  Mehul S Patel; Jen Lee; Manuel Baz; Claire E Wells; Susannah Bloch; Amy Lewis; Anna V Donaldson; Benjamin E Garfield; Nicholas S Hopkinson; Amanda Natanek; William D-C Man; Dominic J Wells; Emma H Baker; Michael I Polkey; Paul R Kemp
Journal:  J Cachexia Sarcopenia Muscle       Date:  2015-12-29       Impact factor: 12.910

10.  Systemic and pulmonary inflammation is independent of skeletal muscle changes in patients with chronic obstructive pulmonary disease.

Authors:  Bethan L Barker; Susan McKenna; Vijay Mistry; Mitesh Pancholi; Hemu Patel; Koirobi Haldar; Michael R Barer; Ian D Pavord; Michael C Steiner; Christopher E Brightling; Mona Bafadhel
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2014-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.